Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo.

Stavrou S, Crawford D, Blouch K, Browne EP, Kohli RM, Ross SR.

PLoS Pathog. 2014 May 22;10(5):e1004145. doi: 10.1371/journal.ppat.1004145. eCollection 2014 May.

2.

Role of the single deaminase domain APOBEC3A in virus restriction, retrotransposition, DNA damage and cancer.

Wang Y, Schmitt K, Guo K, Santiago ML, Stephens EB.

J Gen Virol. 2016 Jan;97(1):1-17. doi: 10.1099/jgv.0.000320. Epub 2015 Oct 20. Review.

PMID:
26489798
3.

Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.

Albin JS, Haché G, Hultquist JF, Brown WL, Harris RS.

J Virol. 2010 Oct;84(19):10209-19. doi: 10.1128/JVI.00632-10. Epub 2010 Aug 4.

4.

Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity.

Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K.

Retrovirology. 2007 Aug 29;4:61.

5.

The effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model.

Cadena C, Stavrou S, Manzoni T, Iyer SS, Bibollet-Ruche F, Zhang W, Hahn BH, Browne EP, Ross SR.

Retrovirology. 2016 Jun 30;13(1):45. doi: 10.1186/s12977-016-0280-y.

6.

The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.

Casartelli N, Guivel-Benhassine F, Bouziat R, Brandler S, Schwartz O, Moris A.

J Exp Med. 2010 Jan 18;207(1):39-49. doi: 10.1084/jem.20091933. Epub 2009 Dec 28.

7.

Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.

He Z, Zhang W, Chen G, Xu R, Yu XF.

J Mol Biol. 2008 Sep 12;381(4):1000-11. doi: 10.1016/j.jmb.2008.06.061. Epub 2008 Jun 28.

PMID:
18619467
8.

HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity.

Wang Y, Kinlock BL, Shao Q, Turner TM, Liu B.

Retrovirology. 2014 Oct 11;11:89. doi: 10.1186/s12977-014-0089-5.

9.

Long-term passage of Vif-null HIV-1 in CD4+ T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance.

Miyagi E, Kao S, Fumitaka M, Buckler-White A, Plishka R, Strebel K.

Virology. 2017 Apr;504:1-11. doi: 10.1016/j.virol.2017.01.016. Epub 2017 Jan 25.

PMID:
28131088
10.

Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.

Wang T, Zhang W, Tian C, Liu B, Yu Y, Ding L, Spearman P, Yu XF.

Virology. 2008 Jul 20;377(1):71-9. doi: 10.1016/j.virol.2008.04.012. Epub 2008 May 21.

11.

A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.

Peng J, Ao Z, Matthews C, Wang X, Ramdahin S, Chen X, Li J, Chen L, He J, Ball B, Fowke K, Plummer F, Embree J, Yao X.

J Mol Biol. 2013 Aug 23;425(16):2840-52. doi: 10.1016/j.jmb.2013.05.015. Epub 2013 May 23.

PMID:
23707381
12.

Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.

Yamashita T, Nomaguchi M, Miyake A, Uchiyama T, Adachi A.

Microbes Infect. 2010 Feb;12(2):166-71. doi: 10.1016/j.micinf.2009.11.007. Epub 2009 Nov 26.

PMID:
19944180
13.

Dissecting APOBEC3G substrate specificity by nucleoside analog interference.

Rausch JW, Chelico L, Goodman MF, Le Grice SF.

J Biol Chem. 2009 Mar 13;284(11):7047-58. doi: 10.1074/jbc.M807258200. Epub 2009 Jan 9.

14.

Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G.

Bélanger K, Langlois MA.

J Gen Virol. 2015 Sep;96(9):2878-87. doi: 10.1099/vir.0.000214. Epub 2015 Jun 5.

PMID:
26048885
15.

Functional domain organization of human APOBEC3G.

Gooch BD, Cullen BR.

Virology. 2008 Sep 15;379(1):118-24. doi: 10.1016/j.virol.2008.06.013. Epub 2008 Jul 18.

16.

Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.

Rose KM, Marin M, Kozak SL, Kabat D.

AIDS Res Hum Retroviruses. 2005 Jul;21(7):611-9.

PMID:
16060832
17.

HIV restriction by APOBEC3 in humanized mice.

Krisko JF, Martinez-Torres F, Foster JL, Garcia JV.

PLoS Pathog. 2013 Mar;9(3):e1003242. doi: 10.1371/journal.ppat.1003242. Epub 2013 Mar 28.

18.

HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.

Smith JL, Izumi T, Borbet TC, Hagedorn AN, Pathak VK.

J Virol. 2014 Sep 1;88(17):9893-908. doi: 10.1128/JVI.01318-14. Epub 2014 Jun 18.

19.

An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA.

Widera M, Erkelenz S, Hillebrand F, Krikoni A, Widera D, Kaisers W, Deenen R, Gombert M, Dellen R, Pfeiffer T, Kaltschmidt B, Münk C, Bosch V, Köhrer K, Schaal H.

J Virol. 2013 Mar;87(5):2707-20. doi: 10.1128/JVI.02755-12. Epub 2012 Dec 19.

20.

Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.

Dang Y, Davis RW, York IA, Zheng YH.

J Virol. 2010 Jun;84(11):5741-50. doi: 10.1128/JVI.00079-10. Epub 2010 Mar 24.

Supplemental Content

Support Center